AXNX - Axonics guides Q4 and FY22 revenue above consensus

• Axonics ( NASDAQ: AXNX ) expects 4Q total net revenue to be range in  $85.6M to $86.0M, an increase of 61% Y/Y, vs consensus of $74.30M .
• Q4 Sacral neuromodulation revenue is expected to be $70.2M to $70.4M, an increase of 58% Y/Y.
• Q4 Bulkamid revenue is expected to be $15.4M to $15.6M, an increase of 78% Y/Y.
• Fiscal year 2022 total net revenue is expected to be in the range of $273.6M, an increase of 52% Y/Y, vs consensus of $262.13M .
• FY22 Sacral neuromodulation revenue is expected to be in the range of $222.0M, an increase of 41% Y/Y.
• FY22 Bulkamid revenue is expected to be in the range of $51.6M, an increase of 127% Y/Y.
• For the fiscal year 2023, the company expects total revenue in the range of $342M vs consensus of $325.40M .

For further details see: